NB-4746 / Nura Bio - LARVOL DELTA

A Phase 1 Drug-Drug Interaction Study to Assess the Interaction Potential of NB-4746 on CYP1A2 and CYP3A4 Substrates in Healthy Volunteers (ANZCTR) - P1 | N=18 | Not yet recruiting | Sponsor: Nura Bio

New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders • CYP1A2 • CYP3A4

Phase 1, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of NB-4746 in Healthy Volunteers (ANZCTR) - P1 | N=66 | Completed | Sponsor: Nura Bio Inc. | Not yet recruiting ➔ Completed

Trial completion • Amyotrophic Lateral Sclerosis • CNS Disorders

Experimental MS therapy NB-4746 to be tested in healthy volunteers (Multiple Sclerosis News Today) - "Nura Bio has launched a Phase 1 clinical trial evaluating NB-4746, its investigational treatment for multiple sclerosis (MS) and several other neurological conditions, in healthy volunteers. The trial’s participants will be randomly assigned to receive single and multiple doses of NB-4746 or a placebo. The goal is to evaluate the safety, tolerability, and pharmacokinetics of the small molecule before it can be moved to clinical trials in people with neurological diseases. Pharmacokinetics refers to the movement of a drug into, through, and out of the body....'We expect to enter clinical trials in a patient population in 2024, to evaluate the impact of NB-4746 on axonal injury and NfL levels.'"

New trial • Trial status • Amyotrophic Lateral Sclerosis • CNS Disorders • Immunology • Multiple Sclerosis • Pain

Phase 1, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of NB-4746 in Healthy Volunteers (ANZCTR) - P1 | N=66 | Not yet recruiting | Sponsor: Nura Bio Inc.

New P1 trial • Amyotrophic Lateral Sclerosis • CNS Disorders